sunitinib stada 37,5 mg cietās kapsulas
stada arzneimittel ag, germany - sunitinibs - kapsula, cietā - 37,5 mg
sunitinib stada 50 mg cietās kapsulas
stada arzneimittel ag, germany - sunitinibs - kapsula, cietā - 50 mg
pazopanib teva 200 mg apvalkotās tabletes
teva b.v., netherlands - pazopanibs - apvalkotā tablete - 200 mg
sorafenib accord
accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastiski līdzekļi - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.
suphrex 12,5 mg cietās kapsulas
lv system service, latvia - sunitinibs - kapsula, cietā - 12,5 mg
suphrex 50 mg cietās kapsulas
lv system service, latvia - sunitinibs - kapsula, cietā - 50 mg
sunitinib be pharma 12,5 mg cietās kapsulas
be pharma d.o.o., slovenia - sunitinibs - kapsula, cietā - 12,5 mg
sunitinib be pharma 25 mg cietās kapsulas
be pharma d.o.o., slovenia - sunitinibs - kapsula, cietā - 25 mg
sunitinib be pharma 37,5 mg cietās kapsulas
be pharma d.o.o., slovenia - sunitinibs - kapsula, cietā - 37,5 mg
sunitinib be pharma 50 mg cietās kapsulas
be pharma d.o.o., slovenia - sunitinibs - kapsula, cietā - 50 mg